Checkmate Pharmaceuticals, Inc. (CMPI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Alan Bash
Employees:
30
245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA 02142
978-503-2124

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Checkmate Pharmaceuticals, Inc. develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 227.123 Million Shares Outstanding21.631 Million Avg 30-day Volume 283.05 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.73
Price to Revenue0.0 Debt to Equity0.0 EBITDA-62.457 Million
Price to Book Value1.2782 Operating Margin0.0 Enterprise Value10.249 Million
Current Ratio5.201 EPS Growth-3.229 Quick Ratio5.027
1 Yr BETA 2.2892 52-week High/Low 10.5 / 2.0 Profit Margin0.0
Operating Cash Flow Growth-13.3807 Altman Z-Score-3.2281 Free Cash Flow to Firm -38.254 Million

Are you looking for this stock instead?

View SEC Filings from CMPI instead.

View recent insider trading info

Checkmate Pharmaceuticals, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CMPI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CMPI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-05-31 by POWELL MICHAEL
  • 4: filed on 2022-05-31 by FLAHERTY KEITH T.
  • 4: filed on 2022-05-31 by ISACOFF OREN
  • 4: filed on 2022-05-31 by COLABUONO PETER
  • 4: filed on 2022-05-31 by YAN JOY
  • 4: filed on 2022-05-31 by DOLSKI ROBERT
  • 4: filed on 2022-05-31 by WOOLDRIDGE JAMES
  • 4: filed on 2022-05-31 by WIGGINTON JON MARC
  • 4: filed on 2022-05-31 by FUHRMAN ALAN
  • 4: filed on 2022-05-31 by BASH ALAN

    • Events (8k)

  • 8-K: filed on 2022-05-31:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-14:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    POWELL MICHAEL

    • Director
    		 0 2022-05-31 1

    FUHRMAN ALAN

    • Director
    		 0 2022-05-31 1

    FLAHERTY KEITH T.

    • Director
    		 0 2022-05-31 1

    WIGGINTON JON MARC

    • Director
    		 0 2022-05-31 1

    WOOLDRIDGE JAMES CHIEF MEDICAL OFFICER

    • Officer
    		 0 2022-05-31 1

    ISACOFF OREN

    • Director
    		 0 2022-05-31 1

    COLABUONO PETER

    • Director
    		 0 2022-05-31 1

    DOLSKI ROBERT CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-05-31 1

    YAN JOY

    • Director
    		 0 2022-05-31 1

    BASH ALAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2022-05-31 1

    VENBIO GLOBAL STRATEGIC FUND II L.P.

    VENBIO GLOBAL STRATEGIC GP II, L.P.

    VENBIO GLOBAL STRATEGIC GP II, LTD.

    GOODMAN COREY S

    ADELMAN ROBERT J

    • 10% Owner
    		 2,155,930 2022-05-13 7

    NOVO HOLDINGS A/S

    • 10% Owner
    		 2,161,990 2022-02-23 0

    LABINGER BARRY PRESIDENT AND CEO

    • Officer
    • Director
    		 85,950 2021-08-04 0

    CHAUDHARY KLEEM CHIEF BUSINESS OFFICER

    • Officer
    		 27,300 2021-08-04 0

    KRIEG ARTHUR M CHIEF SCIENTIFIC OFFICER

    • Officer
    		 815,734 2021-06-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 22:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 21:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 21:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 20:45:04 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 20:15:04 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 19:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 19:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 18:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 18:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 17:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 17:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 16:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 16:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 15:45:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 15:15:03 UTC -17.1895 18.0095 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 14:45:04 UTC -16.6653 17.4853 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 14:15:03 UTC -16.6653 17.4853 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 13:45:03 UTC -16.6653 17.4853 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 13:15:03 UTC -16.6653 17.4853 1500000
    CHECKMATE PHARMACEUTICALS IN CMPI 2022-05-31 12:45:03 UTC -16.6653 17.4853 1500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments